Table 3. Liver function testing at W1 post-treatment.
| Parameters | DEB-TACE group (N=171) | cTACE group (N=164) | P value |
|---|---|---|---|
| ALT (μ/L) | 73.7 (39.4–131.0) | 60.0 (32.8–128.8) | 0.353 |
| ≥1 ULN (n/%) | 117/158 (74.1) | 102/144 (70.8) | 0.532 |
| ≥2 ULN (n/%) | 70/158 (44.3) | 61/144 (42.4) | 0.734 |
| ≥3 ULN (n/%) | 47/158 (29.7) | 40/144 (27.8) | 0.706 |
| AST (μ/L) | 82.0 (44.4–191.0) | 81.3 (41.6–155.5) | 0.392 |
| ≥1 ULN (n/%) | 129/158 (81.6) | 110/144 (76.4) | 0.261 |
| ≥2 ULN (n/%) | 80/158 (50.6) | 74/144 (51.4) | 0.896 |
| ≥3 ULN (n/%) | 63/158 (39.9) | 55/144 (38.2) | 0.765 |
| ALP (μ/L) | 131.0 (95.0–189.0) | 120.0 (86.0–175.0) | 0.218 |
| ≥1 ULN (n/%) | 58/115 (50.4) | 48/113 (42.5) | 0.228 |
| ≥2 ULN (n/%) | 18/115 (15.7) | 14/113 (12.4) | 0.478 |
| ≥3 ULN (n/%) | 9/115 (7.8) | 4/113 (3.5) | 0.163 |
| TBIL (μmol/L) | 27.3 (18.5–40.7) | 21.5 (15.4–30.8) | <0.001 |
| ≥1 ULN (n/%) | 116/158 (73.4) | 83/144 (57.6) | 0.004 |
| ≥2 ULN (n/%) | 46/158 (29.1) | 23/144 (16.0) | 0.007 |
| ≥3 ULN (n/%) | 19/158 (12.0) | 9/144 (6.3) | 0.084 |
| ALB (g/L) | 32.8 (29.7–27.0) | 34.2 (30.3–37.4) | 0.099 |
| ≥1 ULN (n/%) | 2/158 (1.3) | 2/144 (1.4) | 0.926 |
| ≥2 ULN (n/%) | 2/158 (1.3) | 2/144 (1.4) | 0.926 |
| ≥3 ULN (n/%) | 2/158 (1.3) | 1/144 (0.7) | 0.617 |
| TP (g/L) | 61.9 (57.9–66.8) | 62.4 (58.6–66.3) | 0.786 |
| ≥1 ULN (n/%) | 0/157 (0.0) | 1/140 (0.7) | 0.289 |
| ≥2 ULN (n/%) | 0/157 (0.0) | 1/140 (0.7) | 0.289 |
| ≥3 ULN (n/%) | 0/157 (0.0) | 1/140 (0.7) | 0.289 |
| TBA (I/L) | 11.8 (5.2–20.4) | 9.8 (5.2–21.0) | 0.525 |
| ≥1 ULN (n/%) | 82/142 (57.7) | 61/128 (47.7) | 0.097 |
| ≥2 ULN (n/%) | 38/142 (26.8) | 33/128 (25.8) | 0.855 |
| ≥3 ULN (n/%) | 25/142 (17.6) | 19/128 (14.8) | 0.540 |
Data were presented as median (25th–75th quantiles) or count (%). Comparison between 2 groups was determined by Wilcoxon rank sum test or Chi-square test. P value <0.05 was considered significant, and the significant results were shown in boldface. W1, 1 week; DEB-TACE, drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemo-embolization; ALT, alanine aminotransferase; ULN, upper limit of normal; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBIL, total bilirubin; ALB, albumin; TP, total protein; TBA, total bile acid.